**BREAST CLINICAL SERIES LECTURE**

**From Drive-by to Home Recovery: Surgical Updates on Mastectomy Patients**

**Wednesday September 21, 2022 from 3:30PM - 4:30PM**

Join Zoom meeting: [https://yale.zoom.us/j/93772176426?pwd=ek1EUTIBVzZzY0kwWXBUMBzV3Zkdz09](https://yale.zoom.us/j/93772176426?pwd=ek1EUTIBVzZzY0kwWXBUMBzV3Zkdz09)

Or Telephone: 203-432-9666, Meeting ID: 937 7217 6426, Password: 672221

*Education in multidisciplinary breast care, including cancer prevention, genetics, breast surgical oncology, breast med onc, breast rad onc, breast pathology, survivorship, research, multidisciplinary collaborative research, multidisciplinary journal clubs, Breast Program care signature pathways, didactic training*

**Texting code for today’s session: 35147**

**Faculty Speaker:**

**Elizabeth R. Berger, MD, MS**  
Assistant Professor  
Section of Breast Surgery  
Division of Surgical Oncology  
Department of Surgery  
Yale School of Medicine

**Program Objective(s):**

1. Understand the previous conceptions of same-day discharge after mastectomy  
2. Discuss the current practices of home recovery after surgery  
3. Learn about the “aesthetically flat closure” movement

**Target Audience: Breast Oncology multiple specialties, Nursing, Social Work, APPs, trainees etc.**

**Accreditation Statement:** Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Designation Statement:** Yale School of Medicine designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**Mitigation of Financial Relationships Statement:** Yale CME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

**Disclosures on page 2**
## Course Director & Planning Committee:

<table>
<thead>
<tr>
<th>Name of individual</th>
<th>Individual's role in activity</th>
<th>Name of Ineligible Company(s) / Nature of Relationship(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Janine Hoffmann, other</td>
<td>Activity Coordinator</td>
<td>Nothing to disclose - 08/08/2022</td>
</tr>
<tr>
<td>Mehra Golshan, MD/DO</td>
<td>Course Director</td>
<td>Nothing to disclose - 08/08/2022</td>
</tr>
<tr>
<td>Maryam Lustberg, MD, MPH</td>
<td>Course Director</td>
<td>Consulting Fee-Pfizer</td>
</tr>
<tr>
<td>Elizabeth R Berger, MD</td>
<td>Faculty</td>
<td>Nothing to disclose – 09/16/22</td>
</tr>
</tbody>
</table>